Trillium Therapeutics was a Toronto-based clinical-stage immuno-oncology biopharmaceutical company developing cancer therapeutics (notably CD47-targeting agents). It was acquired by Pfizer in August 2021 for approximately $2.2B and no longer operates as an independent entity. - View it on GitHub